Zacks Investment Research upgraded shares of Atossa Genetics (ATOS) from N/A to OUTPERFORM on January 02, 2013, with a target price of $7.50.
Atossa is a pure play breast health testing company with a focused growth strategy. The Company has recently launched FDA cleared MASCT System for NAF collection and two lab testing services, and will launch two new testing services in 2013. We see total revenue growing at 79% CAGR from 2013 to 2018, with the Company turning profitable in 2016 with EPS of $0.05. We see EPS at $0.62 in 2018. We think downside risk is low while upside potential is high at this time. We rate Atossa shares Outperform based on the Company's strong fundamentals.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Atossa Genetics (ATOS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment